title: Efficacy of gadolinium administration in magnetic resonance imaging screening of patients with complex partial seizures and results of a normal neurologic examination.
abstract: OBJECTIVE
  Magnetic resonance imaging has become a standard screening tool in the evaluation of patients with complex partial seizures. This study prospectively addresses the efficacy, if any, of routinely adding gadolinium-enhanced images to routine T2-weighted images in patients with a normal neurologic examination.
  
  
  METHODS
  One hundred consecutive patients with electroencephalogram and clinical evidence of complex partial seizures and no other neurologic abnormalities were examined prospectively with axial and coronal T2-weighted spin-echo images, followed by axial and coronal gadolinium-enhanced T1-weighted scans.
  
  
  RESULTS
  The scans in 73 patients were interpreted as normal, 14 had nonspecific white matter lesions, 5 had asymmetry of the temporal horns, and 2 had asymmetric signal intensity in the temporal lobes, and the scans in 6 showed abnormal gadolinium enhancement. Of the lesions in the six patients whose scans showed abnormal enhancement, four were seen well on the T2-weighted images. Of the remaining two, one was a small cerebellar venous angioma, and the other, a probable tiny convexity meningioma. One temporal lobe glioma seen on the T2 scans did not enhance with gadolinium.
  
  
  CONCLUSIONS
  Routine administration of gadolinium does not appear to be of benefit in imaging patients with complex partial seizures who are otherwise neurologically normal.
authors.affiliation: Department of Diagnostic Radiology, Henry Ford Hospital, Detroit, MI 48202, USA.
authors.forename: W P
authors.initials: WP
authors.lastname: Sanders
authors.forename: R
authors.initials: R
authors.lastname: Silbergleit
authors.forename: E M
authors.initials: EM
authors.lastname: Spickler
authors.forename: G L
authors.initials: GL
authors.lastname: Barkley
authors.forename: B A
authors.initials: BA
authors.lastname: Mehta
mesh_terms: D000328:Adult; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000175:diagnosis; D002528:Cerebellar Neoplasms / Q000175:diagnosis; D003287:Contrast Media; D004338:Drug Combinations; D004569:Electroencephalography; D017029:Epilepsy, Complex Partial / Q000175:diagnosis*; D005682:Gadolinium; D019786:Gadolinium DTPA; D005910:Glioma / Q000175:diagnosis; D006391:Hemangioma / Q000175:diagnosis; D006801:Humans; D007089:Image Enhancement; D008279:Magnetic Resonance Imaging; D008536:Meglumine; D008577:Meningeal Neoplasms / Q000175:diagnosis; D008579:Meningioma / Q000175:diagnosis; D009460:Neurologic Examination; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D011446:Prospective Studies; D013702:Temporal Lobe / Q000473:pathology
chemical_list: D003287:Contrast Media; D004338:Drug Combinations; D009942:Organometallic Compounds; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA